Wnt/β-catenin signaling is a therapeutic target in anaplastic thyroid carcinoma
Endocrine · 28.05.2024 · 86 (1) · 114-118
DOI: 10.1007/s12020-024-03887-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine, online erschienen am 28.05.2024. Verfasst von Diana Diaz und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA. Hauptthemen laut MEDLINE: Thyroid Carcinoma, Anaplastic, Wnt Signaling Pathway, Thyroid Neoplasms, Pyrvinium Compounds. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, ACS, ATA.
Abstract (Originalsprache)
Background
Anaplastic thyroid carcinoma (ATC) is a highly aggressive malignancy that has consistently shown Wnt/β-catenin (canonical) signaling activation in various study populations. There are currently no targetable treatments for BRAF -wildtype ATC and a lack of effective treatment for BRAF V600E ATC. Our aim is to identify whether Wnt inhibitors could be potential therapeutic agents for ATC patients with limited treatment options.
Methods
In this Institutional Review Board-approved study, we utilize a cohort of 32 ATCs and 20 non-neoplastic multinodular goiters (MNG). We also use 4 ATC spheroid cell lines (THJ-16T, THJ-21T, THJ-29T, and THJ-11T) and two primary patient-derived ATC organoid cultures (VWL-T5 and VWL-T60). Finally, we use a murine xenograft mouse model of ATC for in vivo treatment studies.
Results
Using a large patient cohort, we demonstrate that this near-universal Wnt signaling activation is associated with ligand expression- rather than being mutationally-driven. We show that pyrvinium pamoate, a potent Wnt inhibitor, exhibits in vitro efficacy against both ATC cell lines and primary patient-derived ATC organoids VWL-T5 ( p < 0.05) and VWL-T60 ( p < 0.01) Finally, using a murine xenograft model of ATC, we show that pyrvinium significantly delays the growth of ATC tumors in THJ-16T ( p < 0.005) and THJ-21T ( p < 0.001).
Conclusions
We tested Wnt inhibitor treatment, both in vitro and in vivo, as a potential novel therapy for this highly lethal disease. Future large-scale studies utilizing multiple Wnt inhibitors will lay the foundation for the development of these novel therapies for patients with ATC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.
- Department of Pharmacology, Vanderbilt University, Nashville, TN, USA.
- Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA.
- Department of Cell and Developmental Biology, Vanderbilt University, Nashville, TN, USA.
- Department of Surgery, Vanderbilt University Medical Center, Nashville, TN, USA.
- Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Förderung
- NCI NIH HHS
- ACS
- ATA
- NIDDK NIH HHS
- VCORCDP
- NIGMS NIH HHS
- NIH HHS
- NIH
Zitieren
APA
Diaz, D., Bergdorf, K., Loberg, M. A., Phifer, C. J., Xu, G. J., Sheng, Q., Chen, S. C., Byrant, J. M., Tigue, M. L., Hartmann, H., Rohde, S. L., Netterville, J. L., Baregamian, N., Goettel, J. A., Ye, F., Lee, E., & Weiss, V. L. (2024). Wnt/β-catenin signaling is a therapeutic target in anaplastic thyroid carcinoma. Endocrine, 86(1), 114-118. https://doi.org/10.1007/s12020-024-03887-0
Vancouver
Diaz D, Bergdorf K, Loberg MA, Phifer CJ, Xu GJ, Sheng Q, et al. Wnt/β-catenin signaling is a therapeutic target in anaplastic thyroid carcinoma. Endocrine. 2024;86(1):114-118. doi:10.1007/s12020-024-03887-0
BibTeX
@article{Diaz2024,
author = {Diaz, Diana and Bergdorf, Kensey and Loberg, Matthew A and Phifer, Courtney J and Xu, George J and Sheng, Quanhu and Chen, Sheau-Chiann and Byrant, Jamal M and Tigue, Megan L and Hartmann, Heather and Rohde, Sarah L and Netterville, James L and Baregamian, Naira and Goettel, Jeremy A and Ye, Fei and Lee, Ethan and Weiss, Vivian L},
title = {Wnt/β-catenin signaling is a therapeutic target in anaplastic thyroid carcinoma},
journal = {Endocrine},
year = {2024},
volume = {86},
number = {1},
pages = {114--118},
doi = {10.1007/s12020-024-03887-0}
}
EUVIMED